Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
10-K
2023 FY
Annual report
15 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Feb 24
25-NSE
Exchange delisting
15 Feb 24
8-K
Unregistered Sales of Equity Securities
17 Jan 24
8-K
Unregistered Sales of Equity Securities
5 Jan 24
8-K
Unregistered Sales of Equity Securities
3 Jan 24
8-K
Unregistered Sales of Equity Securities
11 Dec 23
RW
Registration withdrawal request
1 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
27 Nov 23
8-K
Entry into a Material Definitive Agreement
22 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
S-1/A
IPO registration (amended)
3 Nov 23
S-1/A
IPO registration (amended)
31 Oct 23
8-K
ZIVO Bioscience Announces Reverse Stock Split
26 Oct 23
S-1
IPO registration
4 Oct 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9 Aug 23
EFFECT
Notice of effectiveness
4 Aug 23
424B3
Prospectus supplement
3 Aug 23
CORRESP
Correspondence with SEC
1 Aug 23
UPLOAD
Letter from SEC
31 Jul 23
S-3
Shelf registration
27 Jul 23
D
$4.00 mm in options / securities to be acquired, sold $4.00 mm, 1 investor
17 Jul 23
8-K
ZIVO Bioscience Announces Pricing of $4.0 Million Registered Direct Offering Priced At-The-Market
6 Jul 23
424B5
Prospectus supplement for primary offering
5 Jul 23
RW
Registration withdrawal request
28 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
26 May 23
10-Q
2023 Q1
Quarterly report
10 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
8-K
ZIVO Bioscience Receives $1 Million Bridge Financing
5 Apr 23
S-1
IPO registration
22 Mar 23
10-K
2022 FY
Annual report
14 Mar 23
8-K
Other Events
10 Feb 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
29 Nov 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
Latest ownership filings
SC 13D/A
STROME MEZZANINE FUND, LP
9 Apr 24
SC 13D
Maggiore Christopher D.
22 Jan 24
4
Alison A Cornell
4 Jan 24
4
Christopher D. Maggiore
2 Jan 24
4
Christopher D. Maggiore
14 Dec 23
4
MARK E STROME
30 Oct 23
SC 13D/A
STROME MEZZANINE FUND, LP
30 Oct 23
4
Alison A Cornell
14 Jun 23
4
Christopher D. Maggiore
14 Jun 23
4
Nola E Masterson
14 Jun 23
4
JOHN BERNARD PAYNE
5 Apr 23
4/A
Christopher D. Maggiore
14 Feb 23
SC 13D/A
Maggiore Christopher D.
14 Feb 23
4
Alison A Cornell
21 Dec 22
4
Nola E Masterson
21 Dec 22
4
JOHN BERNARD PAYNE
20 Dec 22
4
Christopher D. Maggiore
20 Dec 22
4
Alison A Cornell
20 Dec 22
4
JOHN BERNARD PAYNE
20 Dec 22
4
Nola E Masterson
20 Dec 22
4
Alison A Cornell
14 Dec 22
4/A
Nola E Masterson
8 Dec 22
4/A
Christopher D. Maggiore
8 Dec 22
4
Christopher D. Maggiore
19 Sep 22
4
Keith Marchiando
31 Aug 22
4
Alison A Cornell
1 Aug 22
4
Christopher D. Maggiore
1 Aug 22
4
Nola E Masterson
1 Aug 22
4
Christopher D. Maggiore
16 Feb 22
4
JOHN BERNARD PAYNE
28 Jan 22
4
Christopher D. Maggiore
14 Jan 22
4
ANDREW A DAHL
25 Oct 21
4
Christopher D. Maggiore
25 Oct 21
4
JOHN BERNARD PAYNE
25 Oct 21
4
Keith Marchiando
25 Oct 21
4
Nola E Masterson
25 Oct 21
4
JOHN BERNARD PAYNE
15 Oct 21
4
Nola E Masterson
15 Oct 21
4
Christopher D. Maggiore
15 Oct 21
4
Alison A Cornell
15 Oct 21